Micro and nanotechnologies: The little formulations that could

Stiepel, Rebeca T.; Duggan, Eliza; Batty, Cole J.; Ainslie, Kristy M.

doi:10.1002/btm2.10421

Cited by 20 publications

(16 citation statements)

References 248 publications

(274 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ionic interaction of mRNA and charged lipids results in a self-assembled nanoparticle that can be formed continuously through microfluidics. 78 These lipid complexes have existed for a long time, 79 but the addition of novel ionizable lipids in the LNPs, as well as more stable mRNA constructs, has resulted in enhanced protective efficacy and translation of the platforms for clinical use. However, LNPs face storage challenges, illustrated by the initial ultracold storage requirements for Pfizer's vaccine (−90 °C and −60 °C), later revised to freezer storage (−50 °C and −15 °C).…”

Section: ■ Encapsulation In Organic Matricesmentioning

confidence: 99%

Clinical and Preclinical Methods of Heat-Stabilization of Human Vaccines

Williamson,

Bachelder,

Ainslie

2024

Mol. Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Vaccines have historically faced challenges regarding stability, especially in regions lacking a robust cold chain infrastructure. This review delves into established and emergent techniques to improve the thermostability of vaccines. We discuss the widely practiced lyophilization method, effectively transforming liquid vaccine formulations into a solid powdered state, enhancing storage and transportation ability. However, potential protein denaturation during lyophilization necessitates alternative stabilization methods. Cryoprotectants, namely, starch and sugar molecules, have shown promise in protecting vaccine antigens and adjuvants from denaturation and augmenting the stability of biologics during freeze-drying. Biomineralization, a less studied yet innovative approach, utilizes inorganic or organic−inorganic hybrids to encapsulate biological components of vaccines with a particular emphasis on metal−organic coordination polymers. Encapsulation in organic matrices to form particles or microneedles have also been studied in the context of vaccine thermostability, showing some ability to store outside the cold-chain. Unfortunately, few of these techniques have advanced to clinical trials that evaluate differences in storage conditions. Nonetheless, early trials suggest that alternative storage techniques are viable and emphasize the need for more comprehensive studies. This review underscores the pressing need for heat-stable vaccines, especially in light of the increasing global distribution challenges. Combining traditional methods with novel approaches holds promise for the future adaptability of vaccine distribution and use.

show abstract

Section: ■ Encapsulation In Organic Matricesmentioning

confidence: 99%

Clinical and Preclinical Methods of Heat-Stabilization of Human Vaccines

Williamson,

Bachelder,

Ainslie

2024

Mol. Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…To date, different DDSs have been generated with that idea in mind; ranging from inorganic nanoparticles to cell based-systems. Indeed, Stiepel et al deeply revised all micro-nanotechnologies employed in the last years as clinically relevant platforms for drug delivery porpoises (Stiepel et al, 2022). Regarding their use in neurodegenerative diseases, recent reviews have summarized the main outcome of different nano-DDS in AD and PD treatment (Akhtar et al, 2021).…”

Section: Synthetic Drug Delivery Systems (Dds) To Target the Cns: Pol...mentioning

confidence: 99%

Targeting the central nervous system: From synthetic nanoparticles to extracellular vesicles—Focus on Alzheimer's and Parkinson's disease

Hernando

Santos‐Vizcaíno

Igartua

et al. 2023

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Neurodegenerative diseases (NDs) such as Alzheimer's disease (AD) and Parkinson's disease (PD) are an accelerating global health problem as life expectancy rises worldwide. Despite their significant burden in public health systems to date, the existing treatments only manage the symptoms without slowing down disease progression. Thus, the ongoing neurodegenerative process remains untreated. Moreover, the stronghold of the brain—the blood–brain barrier (BBB)—prevents drug penetrance and dwindles effective treatments. In the last years, nanotechnology‐based drug delivery systems (DDS) have become a promising approach to target and treat these disorders related to the central nervous system (CNS). PLGA based nanoparticles (NPs) were the first employed DDS for effective drug delivery. However, the poor drug loading capacity and localized immunogenicity prompted the scientific community to move to another DDS such as lipid‐based NPs. Despite the lipid NPs' safety and effectiveness, their off‐target accumulation together with the denominated CARPA (complement activation‐related pseudo allergy) reaction has limited their complete clinical translation. Recently, biological NPs naturally secreted by cells, termed as extracellular vesicles (EVs) have emerged as promising more complex biocompatible DDS. In addition, EVs act as dual players in NDs treatment, as a “cell free” therapy themselves, as well as new biological NPs with numerous characteristics that qualify them as promising carriers over synthetic DDS. The present review aims to display advantages, drawbacks, current limitations and future prospective of the previously cited synthetic and biological DDS to enter the brain and treat one of 21st century most challenging diseases, NDs.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease

show abstract

“…100 nm (Dolez, 2015). However, this definition is often considered too restrictive since several clinically approved nanomedicines exceed 100 nm, such as Abraxane (130 nm) and others, as reviewed elsewhere (Stiepel et al, 2022).…”

Section: Nanomedicine To Combat the Limitations Of Gbm Therapeuticsmentioning

confidence: 99%

“…The US National Institutes of Health (NIH) standards, in turn, limit the definition of nanomedicine to nanotechnologies applied to medicine in the size range between 1 and 100 nm (Dolez, 2015). However, this definition is often considered too restrictive since several clinically approved nanomedicines exceed 100 nm, such as Abraxane (130 nm) and others, as reviewed elsewhere (Stiepel et al, 2022).…”

Section: Nanomedicine To Combat the Limitations Of Gbm Therapeuticsmentioning

confidence: 99%

Multi‐ligand functionalized blood‐to‐tumor sequential targeting strategies in the field of glioblastoma nanomedicine

Martins

Sarmento

2023

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Glioblastoma (GBM) is an unmet clinical need characterized by a standard of care (SOC) 5‐year survival rate of only 5%, and a treatment mostly palliative. Significant hurdles in GBM therapies include an effective penetration of therapeutics through the brain protective barrier, namely the blood–brain barrier (BBB), and a successful therapeutic delivery to brain‐invading tumor cells post‐BBB crossing. These hurdles, along with the poor prognosis and critical heterogeneity of the disease, have shifted attention to treatment modalities with capacity to precisely and sequentially target (i) BBB cells, inducing blood‐to‐brain transport, and (ii) GBM cells, leading to a higher therapeutic accumulation at the tumor site. This sequential targeting allows therapeutic molecules to reach the brain parenchyma and compromise molecular processes that support tumor cell invasion. Besides improving formulation and pharmacokinetics constraints of drugs, nanomedicines offer the possibility of being surface functionalized with multiple possibilities of targeting ligands, while delivering the desired therapeutic cargos to the biological sites of interest. Targeting ligands exploit the site‐specific expression or overexpression of specific molecules on BBB and GBM cells, triggering brain plus tumor transport. Since the efficacy of single‐ligand functionalized nanomedicines is limited due to the GBM anatomical site (brain) and disease complexity, this review presents an overview of multi‐ligand functionalized, BBB and GBM sequentially‐ and dual‐targeted nanomedicines reported in literature over the last 10 years. The role of the BBB in GBM progression, treatment options, and the multiple possibilities of currently available targeting ligands will be summarized.This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Micro and nanotechnologies: The little formulations that could

Cited by 20 publications

References 248 publications

Clinical and Preclinical Methods of Heat-Stabilization of Human Vaccines

Clinical and Preclinical Methods of Heat-Stabilization of Human Vaccines

Targeting the central nervous system: From synthetic nanoparticles to extracellular vesicles—Focus on Alzheimer's and Parkinson's disease

Multi‐ligand functionalized blood‐to‐tumor sequential targeting strategies in the field of glioblastoma nanomedicine

Contact Info

Product

Resources

About